Abstract 4543: Reverse Remodeling with SGLT2 Inhibition on Cardiac MRI in Heart Failure A Meta Analysis of Randomized Trials
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.4543 ↗Auf einen Blick
Zehn RCTs mit 868 Patient:innen zeigen unter SGLT2-Inhibitoren im CMR eine kleine, aber signifikante Reverse-Remodelling-Verbesserung: LVEF stieg, LVESV und LV-Masse sanken.
Fragestellung
Verbessern SGLT2-Inhibitoren bei Herzinsuffizienz im Vergleich zu Placebo strukturelle CMR-Parameter des Myokards?
Methode
Systematische Übersichtsarbeit mit Metaanalyse randomisierter kontrollierter Studien; Suche in PubMed, EMBASE und Cochrane; gepoolte Mittelwertänderungen mit Random-Effects-Modellen.
Ergebnisse
10 RCTs (n = 868). LVEF: MD +1,90; 95 %-KI 0,63 bis 3,17; P = 0,003. LVESV: MD –6,41 mL; 95 %-KI –12,11 bis –0,71; P = 0,03. LVM: MD –6,34 g; 95 %-KI –10,21 bis –2,47; P = 0,001.
Schlussfolgerung der Autor:innen
SGLT2-Hemmung war im CMR mit einem moderaten, aber signifikanten Reverse-Remodelling verbunden, mit besserer systolischer Funktion und geringerer LV-Masse.
Kernaussagen
- LVEF nahm unter SGLT2-Inhibitoren zu
- LVESV und LV-Masse nahmen ab
- Keine signifikanten Unterschiede für LVEDV, LVEDVi, LVESVi, LVMi oder LAVi
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Hasan Alajmi und 5 weiteren Autor:innen.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in heart failure (HF), yet their structural effects on the myocardium remain incompletely defined. Cardiac MRI (CMR) provides precise quantification of ventricular volumes and mass, enabling differentiation between true reverse remodeling and loading effects.
Methods
We systematically searched PubMed, EMBASE, and Cochrane for randomized controlled trials comparing SGLT2 inhibitors with placebo in HF patients undergoing serial CMR. Eligible studies reported changes in ventricular structure or function. Outcomes included LVEF, LV end-systolic volume (LVESV), LV end-diastolic volume (LVEDV), LV mass (LVM), their indexed measures (LVESVi, LVEDVi, LVMi), and left atrial volume index (LAVi). Mean changes from baseline were pooled using random-effects models (DerSimonian-Laird).
Results
Ten RCTs (n = 868) were included. SGLT2 inhibitors significantly improved LVEF (MD +1.90; 95% CI 0.63 to 3.17; P = 0.003) and reduced LVESV (MD –6.41 mL; 95% CI –12.11 to –0.71; P = 0.03) and LVM (MD –6.34 g; 95% CI –10.21 to –2.47; P = 0.001). No significant differences were observed in LVEDV (MD +0.85 mL; P = 0.83), LVEDVi, LVESVi, LVMi, or LAVi. Heterogeneity was low to moderate, and results remained consistent on sensitivity analyses.
Conclusions
SGLT2 inhibition is associated with modest but significant reverse remodeling on CMR, characterized by improved systolic function and reduced LV mass. The discordance between absolute and indexed parameters suggests contributions from both intrinsic myocardial effects and loading conditions. Further studies incorporating T1 mapping and extracellular volume are needed to define antifibrotic mechanisms.
Zitieren
APA
Alajmi, H., Sherwani, M. R. K., Arobo, A., Raza, M., Mansour, M., & Alenezi, F. (2026). Abstract 4543: Reverse Remodeling with SGLT2 Inhibition on Cardiac MRI in Heart Failure A Meta Analysis of Randomized Trials. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.4543
Vancouver
Alajmi H, Sherwani MRK, Arobo A, Raza M, Mansour M, Alenezi F. Abstract 4543: Reverse Remodeling with SGLT2 Inhibition on Cardiac MRI in Heart Failure A Meta Analysis of Randomized Trials. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.4543
BibTeX
@article{Alajmi2026,
author = {Alajmi, Hasan and Sherwani, Mifrah Rahat Khan and Arobo, Ayodeji and Raza, Mubashir and Mansour, Mohamed and Alenezi, Fawaz},
title = {Abstract 4543: Reverse Remodeling with SGLT2 Inhibition on Cardiac MRI in Heart Failure A Meta Analysis of Randomized Trials},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.4543}
}
EUVIMED